2024 年至 2031 年原位杂化市场（按技术、应用、最终用户和地区划分）

原位杂交市场评估，2024-2031

由于原位杂交 (ISH) 在包括癌症在内的多种疾病的检测和研究中具有重要意义，因此对其的需求日益增长。 ISH 是一种先进的技术，可以帮助科学家和医疗专业人员识别组织切片内的特定核酸序列。该技术对于检测基因异常、传染性病原体以及天然组织中特定基因的表达至关重要。随着癌症和其他遗传疾病的发生率上升，对ISH 等精确可靠的诊断方法的需求将不断增长，推动市场收入在2024 年超过18.1 亿美元，到2031 年达到18.1 亿美元。估值至约 33.8 亿美元。

将 ISH 与其他现代诊断技术（如免疫组织化学和下一代定序）结合，可以更全面地瞭解疾病的病理生理学。这种综合方法在个人化医疗中特别有用，因为广泛的分子分析对于根据个别患者制定治疗方案至关重要。因此，ISH 研究在临床诊断、转化研究和药物发现中日益广泛的应用，正在推动医疗保健和生物技术行业的需求，预计 2024 年至 2031 年期间的复合年增长率为 8.97%。

原位杂交市场定义/概述

原位杂交 (ISH) 是一种有效的科学技术，用于检测组织片段或细胞等样本内的 DNA 或 RNA 特定序列。 "In Situ" 一词的意思是 "原位" ，这种技术使科学家能够精确定位这些遗传元素在其生物环境中的具体位置。以RNA 的形式）在何处）位于组织细胞中，为瞭解基因表现模式和细胞功能提供了重要依据。

原位杂交经常用于研究和医学诊断，因为它可以提供空间和分子资讯。其主要应用之一是在发育生物学领域，有助于瞭解基因在生物体生长发育过程中如何受到调控和表现。

ISH 的未来应用有望为包括医学诊断和研究在内的各个领域带来变革性的变化。最有趣的未来应用之一是个人化医疗。随着医疗保健领域转向更个人化的治疗策略，ISH 在发现与包括癌症在内的各种疾病相关的特定遗传标记方面可以发挥重要作用。

遗传疾病和癌症发生率的不断上升会推动原位杂交市场的发展吗？

遗传疾病和癌症发生率的不断上升是原位杂交 (ISH) 业务的主要推动力。根据世界卫生组织（WHO）的数据，癌症是全球第二大死因，到2020年将有约1,000万人死于癌症。全球癌症发生率的不断上升使得人们必须使用 ISH 等现代诊断技术来可靠地检测和表征肿瘤。美国国家癌症研究所估计，39.5% 的男性和女性在一生中的某个阶段会被诊断出罹患癌症。这种较高的终生风险凸显了对 ISH 等精准诊断技术日益增长的需求。

对个人化治疗和标靶药物的日益重视也促进了 ISH 市场的扩张。据美国国立卫生研究院（NIH）称，基因医学的发展已经促成了300多种针对包括癌症在内的各种疾病的定製药物的开发。 ISH 技术对于寻找遗传标记和生物标记以预测治疗决策和患者结果至关重要。此外，老年人口不断增长，更容易患上遗传疾病和癌症，这也推动了对 ISH 技术的需求。联合国预测，到 2050 年，全球每六人中就有一人年龄超过 65 岁，而 2019 年这一数字为每 11 人中就有一人。

熟练专业人员的短缺会阻碍原位杂交市场的发展吗？

合格专业人员的短缺可能会影响原位杂交 (ISH) 市场。然而，一些因素似乎有助于消除这种担忧。首先，对精准医疗和个人化医疗保健的日益重视推动了对 ISH 等分子诊断工具的需求。据美国国立卫生研究院称，精准医疗计画在全国招募超过 100 万名志愿者进行研究，以强调个人化治疗的必要性。这一趋势必将鼓励更多的专业人士专注于相关职业。此外，ISH 技术的进步（例如自动化仪器和简化协议的创建）使得更广泛的实验室人员能够使用这种方法。

此外，教育机构和行业协会正在积极努力缩小技能差距。美国临床病理学会 (ASCP) 报告称，2013 年至 2018 年间，完成认证计画的实验室专业人员数量增加了 7.1%。此外，美国劳工统计局预测，2019 年至 2029 年间，医学实验室技术人员和临床实验室科学家技术人员的就业机会将增加 7%，高于整体平均水准。这种增长表明专门从事 ISH 程序的潜在专家数量正在增加。此外，交叉培训计划和继续教育机会变得越来越普遍，使现有实验室员工能够拓宽他们的技能。

目录

第 1 章简介

• 市场定义
• 市场区隔
• 研究方法

第 2 章执行摘要

• 主要发现 市场概况
• 市场亮点

第3章 市场概览

• 市场规模与成长潜力
• 市场趋势
• 市场推动因素
• 市场限制
• 市场机会
• 波特五力分析

第 4 章 原位杂化市场（依技术划分）

萤光原位杂交 (FISH) 显色原位杂交 (CISH)
• 放射性原位杂交（RISH）

第 5 章：原位杂化市场（按应用）

• 癌症诊断和监测
• 神经科学
• 传染病诊断
• 产前检查
• 药物发现与开发

第6章 原位杂化市场（依最终用户）

• 医院和诊断实验室
• 生物製药公司
• 学术和研究机构

第 7 章 区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利 亚太地区
• 中国
• 日本
• 印度
• 澳大利亚
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合大公国

第 8 章 市场动态

• 市场推动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第 9 章 竞争格局

• 大型公司
• 市占率分析

第10章 公司简介

• Abbott Laboratories
• Agilent Technologies
• F. Hoffmann-La Roche Ltd
• Merck KGaA
• Illumina Inc.
• PerkinElmer Inc.
• NanoString Technologies Inc.
• Advanced Cell Diagnostics Inc.
• Leica Biosystems GmbH
• DiaGenode SA

第 11 章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第 12 章附录

• 缩写列表
• 来源与参考文献

In Situ Hybridization Market Valuation - 2024-2031

The growing need for In Situ Hybridization (ISH) is motivated by its importance in detecting and researching numerous diseases including cancer. ISH is a sophisticated technology that enables scientists and medical practitioners to identify specific nucleic acid sequences within tissue slices. This skill is critical for detecting genetic anomalies, infectious agents, and the expression of certain genes in their natural tissue context. As the incidence of cancer and other genetic illnesses rises, the necessity for precise and dependable diagnostic methods like ISH grows by enabling the market to surpass a revenue of USD 1.81 Billion valued in 2024 and reach a valuation of around USD 3.38 Billion by 2031.

The combination of ISH and other modern diagnostic techniques such as immunohistochemistry and next-generation sequencing is yielding more comprehensive insights into disease pathophysiology. This comprehensive method is especially useful in personalized medicine where extensive molecular profiling is essential for personalizing treatments to individual patients. As a result, ISH's rising applications in clinical diagnostics, translational research, and drug discovery are driving up demand in the healthcare and biotechnology industries by enabling the market to grow at aCAGR of 8.97% from 2024 to 2031.

In Situ Hybridization Market: Definition/ Overview

In situ hybridization (ISH) is an effective scientific technique for detecting specific sequences of DNA or RNA within a sample such as a tissue segment or a cell. The phrase "in situ" means "in place," implying that this technology enables scientists to pinpoint the specific location of these genetic elements inside the biological milieu. Essentially, ISH allows researchers to see where certain genes or their activity (in the form of RNA) are situated in a tissue's cells providing vital insights into gene expression patterns and cellular function.

In situ hybridization is frequently utilized in research and medical diagnostics because of its ability to offer both spatial and molecular information. One of its key applications is in the field of developmental biology where it assists scientists in understanding how genes are regulated and expressed throughout organismal growth and development.

The future application of ISH is expected to transform a variety of disciplines including medical diagnostics and research. One of the most intriguing future uses is personalized medicine. As the healthcare sector shifts toward more personalized treatment strategies, ISH can play an important role in discovering specific genetic markers linked to various diseases including cancer.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Rising Incidence of Genetic Disorders and Cancer Drive the In Situ Hybridization Market?

The increasing incidence of genetic diseases and cancer is a major driver of the in situ hybridization (ISH) business. According to the World Health Organization (WHO), cancer is the world's second biggest cause of death accounting for roughly 10 million deaths by 2020. The rising global cancer incidence needs the use of modern diagnostic techniques such as ISH for reliable tumor detection and characterization. The National Cancer Institute estimates that 39.5% of men and women will be diagnosed with cancer at some point in their lives. This high lifetime risk highlights the increasing need for precise diagnostic techniques like ISH.

The growing emphasis on individualized treatment and targeted medicines also helps to expand the ISH market. The National Institutes of Health (NIH) says that developments in genetic medicine have resulted in the development of over 300 tailored drugs for a variety of disorders including cancer. ISH techniques are critical for finding genetic markers and biomarkers that inform therapy decisions and predict patient outcomes. Furthermore, the expanding older population which is more vulnerable to genetic illnesses and cancer increases the demand for ISH technology. The United Nations projects that by 2050, one in every six persons worldwide will be beyond the age of 65, up from one in every eleven in 2019.

Will Shortage of Skilled Professionals Hamper the In Situ Hybridization Market?

A shortage of competent specialists could influence the in situ hybridization (ISH) market; however, numerous factors may help to offset this concern. First, the growing emphasis on precision medicine and individualized healthcare is increasing demand for molecular diagnostic tools such as ISH. According to the National Institutes of Health, the Precision Medicine Initiative intends to enroll 1 million or more volunteers in a national study cohort emphasizing the need for personalized treatment procedures. This tendency will certainly encourage more professionals to specialize in related professions. Furthermore, advances in ISH technology such as the creation of automated equipment and streamlined protocols are making the approach more accessible to a wider spectrum of laboratory personnel.

Additionally, educational institutions and industry associations are actively attempting to close the skills gap. The American Society for Clinical Pathology (ASCP) reported a 7.1% rise in the number of laboratory professionals who completed certification programs between 2013 and 2018. Furthermore, the U.S. Bureau of Labor Statistics predicts that medical and clinical laboratory technologist and technician jobs will expand by 7% between 2019 and 2029 faster than the overall average. This increase indicates an expanding pool of potential specialists who could specialize in ISH procedures. Furthermore, cross-training programs and continuing education opportunities are becoming more common allowing current laboratory employees to broaden their skill sets.

Category-Wise Acumens

Will the Development of Advanced Fluorescent Dyes and Imaging Technologies Influence the Technique Segment?

Fluorescent chromogenic in situ hybridization (CISH) is also an important technique, however it is less prevalent than FISH. CISH employs chromogenic substrates to provide a visible color reaction that is persistent and easy to interpret using a conventional light microscope. This method is especially useful in pathology laboratories for tissue-based analysis where persistent staining is required for long-term storage and examination of samples. While CISH has advantages in terms of visibility and ease of use, it does not match FISH's multiplexing capability and sensitivity.

In Situ, Hybridization (FISH) is currently the most common technique. FISH's extensive adoption and supremacy can be due to its great sensitivity, adaptability, and ability to perform multiplexing. This technology uses fluorescently labeled probes that bind to specific nucleic acid sequences within cells or tissues allowing researchers and physicians to observe and evaluate several targets at the same time using sophisticated fluorescence microscopy. FISH is especially useful in cytogenetics, where it is used to detect chromosomal abnormalities, and in cancer research to find genetic alterations and gene amplifications. Its ability to produce precise and consistent results makes it a popular choice in both clinical diagnosis and research contexts.

Will the Increasing Demand for Oncological Research and Clinical Practice Drive Growth in the Application Segment?

The demand for in situ hybridization for cancer diagnosis and research is one of the primary applications. This dominance stems from ISH's crucial role in detecting and defining specific genetic changes linked to distinct malignancies. Cancer research and diagnosis greatly benefit from ISH's capacity to detect gene amplifications, translocations, and biomarker expression levels in tissue samples. For example, ISH techniques are critical for identifying malignancies such as breast cancer as they can detect HER2 gene amplifications and guide therapy options. The rising global prevalence of cancer combined with a growing emphasis on individualized care fuels the demand for precise and dependable diagnostic techniques such as ISH. Furthermore, advances in ISH technology have improved its potential to deliver deep molecular insights which are critical for creating targeted medicines and improving patient outcomes.

Neuroscience is another important application, however not as prevalent as cancer diagnosis. ISH is used in neuroscience to analyze gene expression patterns in the brain and nervous system which is critical for understanding neurological illnesses and brain development. Researchers utilize ISH to map gene expression in different brain regions revealing information about illnesses including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. The detailed spatial resolution of ISH enables scientists to explore how specific genes influence brain function and pathology, hence contributing to the creation of new treatments. While neurology is a rising and essential sector for ISH applications, cancer diagnosis remains the principal market driver owing to the urgent and high-impact clinical demand for precise and actionable cancer-related genetic information.

Country/Region-wise Acumens

Will Technologically Upgraded Infrastructure Drive the Growth in the North American Region?

The in situ hybridization (ISH) market in North America is expected to grow significantly owing mostly to technical advancements in infrastructure. The region's rising cancer prevalence is a significant driver. The American Cancer Society estimates that in 2023, there will be 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States alone. Given the high incidence rate, improved diagnostic approaches such as ISH are required for reliable detection and treatment planning. Furthermore, the expanding use of personalized medicine approaches is increasing the demand for ISH procedures. According to the National Institutes of Health, precision medicine programs have garnered more than USD 200 Million in funding since 2015, demonstrating the value of personalized therapy tactics.

Another key contributor is North America's strong research and development infrastructure. The United States leads the world in biomedical research funding with the National Institutes of Health budget reaching USD 45 Billion by 2021. This significant investment encourages advancements in ISH technologies and applications. Furthermore, the presence of large pharmaceutical and biotechnology companies in the region helps to drive market expansion. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), the US biopharmaceutical sector will invest an estimated USD 102.3 Billion in R&D in 2021, with a large amount of that going toward developing and implementing advanced diagnostic technologies such as ISH. The region's supremacy in the ISH market is also due to its well-developed healthcare infrastructure and high healthcare spending.

Will the Investments by Manufacturers & Government Boost the Market in the Asia Pacific Region?

The Asia Pacific region is poised for significant growth in the in situ hybridization (ISH) market. According to the World Health Organization, new cancer cases in Asia are expected to increase from 8.8 million in 2018 to 11.5 million by 2025. This dangerous trend has spurred manufacturers and governments to make significant investments in advanced diagnostic technologies such as ISH. For example, the Japanese government has set aside approximately 46 billion yen (approximately USD 415 Million) on cancer research and development in its 2021 budget.

Another important driver is the rapid expansion of healthcare infrastructure and rising healthcare spending in emerging economies. The Indian government, for example, has stated plans to expand healthcare spending to 2.5% of GDP by 2025, up from 1.5% today. This increase in spending is anticipated to drive up the use of advanced diagnostic procedures such as ISH. Additionally, the increased emphasis on customized medicine and tailored therapies is driving up demand for ISH approaches. According to a report by the Asia Pacific Personalized Medicine Coalition, the region's personalized medicine market is predicted to develop at a CAGR of 15.6% from 2021-2026.

Competitive Landscape

The in situ hybridization market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the in situ hybridization market include:

Thermo Fisher Scientific, Inc.

Abbott

PerkinElmer, Inc.

BioView

Agilent Technologies, Inc.

Merck KGaA

Bio-Rad Laboratories, Inc.

Latest Developments

In January 2023, Ikonisys SA teamed with Integrated Gulf Biosystems Group (IGB) to distribute the Ikoniscope20 Digital Fluorescence Microscope Solution in the Middle East, including Saudi Arabia, the UAE, Kuwait, Bahrain, and South Asian regions. This agreement intends to increase the reach of Ikonisys' oncology testing products.

In February 2023, Molecular Instruments, a spin-off of the California Institute of Technology introduced HCR RNA-CISH kits to improve automated chromogenic ISH procedures using RNAscope. These kits enable a double turnaround time at half the cost.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. In Situ Hybridization Market, By Technique

• Fluorescent In Situ Hybridization (FISH)
• Chromogenic In Situ Hybridization (CISH)
• Radioactive In Situ Hybridization (RISH)

5. In Situ Hybridization Market, By Application

• Cancer Diagnosis and Research
• Neuroscience
• Infectious Disease Diagnosis
• Prenatal Testing
• Drug Discovery and Development

6. In Situ Hybridization Market, By End-User

• Hospitals and Diagnostic Laboratories
• Biopharmaceutical Companies
• Academic and Research Institutes

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Abbott Laboratories
• Agilent Technologies
• F. Hoffmann-La Roche Ltd
• Merck KGaA
• Illumina Inc.
• PerkinElmer Inc.
• NanoString Technologies Inc.
• Advanced Cell Diagnostics Inc.
• Leica Biosystems GmbH
• DiaGenode SA

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References